Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

31.69 -2.18 (-6.44%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

48 49 Next >

Hims & Hers Health (HIMS) Shares Skyrocket, What You Need To Know

April 29, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk announced plans to offer its weight loss drug Wegovy through the company's (Hims &...

Via StockStory

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 29, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 29, 2025

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform ↗

April 29, 2025

Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.

Via Benzinga

Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings ↗

April 29, 2025

Via Benzinga

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday ↗

April 29, 2025

Via Benzinga

Top movers in Tuesday's pre-market session ↗

April 29, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators ↗

April 29, 2025

Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers.

Via Stocktwits

Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy ↗

April 29, 2025

The companies will collaborate to improve access to weight-loss drugs in the U.S.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care

April 29, 2025

From Hims & Hers

Via Business Wire

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

Breaking Down Hims & Hers Health: 13 Analysts Share Their Views ↗

April 25, 2025

Via Benzinga

2 Reasons to Like HIMS and 1 to Stay Skeptical

April 23, 2025

Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per...

Via StockStory

Topics Stocks

Is the Market Bullish or Bearish on Hims & Hers Health? ↗

April 21, 2025

Via Benzinga

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide ↗

April 17, 2025

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Via The Motley Fool

Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers

April 17, 2025

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.

Via StockStory

Robinhood, AppLovin, Hims & Hers Health, Sleep Number, and Covenant Logistics Shares Plummet, What You Need To Know

April 16, 2025

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that...

Via StockStory

Topics Economy Government World Trade

Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

April 14, 2025

From Hims & Hers

Via Business Wire

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

April 10, 2025

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Via MarketBeat

Exploring the Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS) as It Nears a Breakout. ↗

April 10, 2025

Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating.

Via Chartmill

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

April 09, 2025

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most...

Via StockStory

Topics Artificial Intelligence Government World Trade

Why Hims & Hers Health Stock Couldn't Beat the Market Today ↗

April 02, 2025

Via The Motley Fool

What's Driving the Market Sentiment Around Hims & Hers Health? ↗

April 02, 2025

Via Benzinga

Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch ↗

April 02, 2025

It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.

Via Investor's Business Daily

nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 02, 2025

Via Benzinga

Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

April 01, 2025

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07.

Via Benzinga

Topics Stocks

Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact ↗

April 01, 2025

According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug.

Via Stocktwits

Why Hims & Hers Health Stock Soared Tuesday ↗

April 01, 2025

Via The Motley Fool

Topics Stocks

Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened? ↗

April 01, 2025

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

All News about Hims & Hers Health, Inc. Class A Common Stock

Popular Pages